Literature DB >> 14626495

Cysteinyl-leukotrienes and the liver.

Ramin Farzaneh-Far1, Kevin Moore.   

Abstract

Leukotrienes are potent biological mediators implicated in an increasing number of disease processes. This review outlines the basic biology of leukotrienes and discusses recent developments in our understanding of the specific role of cysteinyl-leukotrienes (cLTs) in cholestasis, hepatic inflammation, portal hypertension, and the pathogenesis of the hepatorenal syndrome (HRS).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14626495     DOI： 10.1016/s1098-8823(03)00076-5

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN： 1098-8823            Impact factor:   3.072


  7 in total

Review 1.  Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research.

Authors:  Simon C Ling; Thomas Walters; Patrick J McKiernan; Kathleen B Schwarz; Guadalupe Garcia-Tsao; Benjamin L Shneider
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-03       Impact factor: 2.839

2.  Enhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure model.

Authors:  Kui-Fen Ma; Hong-Yu Yang; Zhe Chen; Luo-Yang Qi; Dan-Yan Zhu; Yi-Jia Lou
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

3.  Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.

Authors:  Kirsten M Williams; Steven Z Pavletic; Stephanie J Lee; Paul J Martin; Don E Farthing; Frances T Hakim; Jeremy Rose; Beryl L Manning-Geist; Juan C Gea-Banacloche; Leora E Comis; Edward W Cowen; David G Justus; Kristin Baird; Guang-Shing Cheng; Daniele Avila; Seth M Steinberg; Sandra A Mitchell; Ronald E Gress
Journal:  Transplant Cell Ther       Date:  2022-02-01

4.  Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation.

Authors:  Lu Li; Yi-Rong Liu; Shan Gao; Jun-Feng Li; Shan-Shan Li; Dan-Dan Zhang; Shuang Liu; Li Bai; Su-Jun Zheng; Zhong-Ping Duan; Min Qi; Yu Chen
Journal:  J Immunol Res       Date:  2014-06-01       Impact factor: 4.818

5.  The Effect of Montelukast on Liver Damage in an Experimental Obstructive Jaundice Model.

Authors:  Serdar Kuru; Kemal Kismet; Aziz M Barlas; Salih Tuncal; Pinar Celepli; Hatice Surer; Elmas Ogus; Ertugrul Ertas
Journal:  Viszeralmedizin       Date:  2015-04-09

6.  Participation of 5-lipoxygenase and LTB4 in liver regeneration after partial hepatectomy.

Authors:  Florencia Lorenzetti; Marina Cecilia Vera; María Paula Ceballos; María Teresa Ronco; Gerardo Bruno Pisani; Juan Alberto Monti; Alvaro Lucci; Carla Gabriela Comanzo; Thierry Tordjmann; María Cristina Carrillo; Ariel Darío Quiroga; María de Luján Alvarez
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

7.  MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication.

Authors:  Isaac Ruiz; Quentin Nevers; Eva Hernández; Nazim Ahnou; Rozenn Brillet; Laurent Softic; Flora Donati; Francois Berry; Sabah Hamadat; Slim Fourati; Jean-Michel Pawlotsky; Abdelhakim Ahmed-Belkacem
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.